Blame your buddy JP for voting YES for the A/S inc
Post# of 30028
How did you vote?
Despite your concerns, I voted YES, as did most everyone here. I felt the long-term benefits would outweigh any short-term impact. It was clear to me a pre-revenue biotech company would need shares to survive and reach the point of revenue generation from multiple assets in the pipeline.
That being said, I would really like to see some non-dilutive funding as has been to date an unmet goal. With Randall Grimes' impressive background, I'm surprised we haven't seen progress in this area over the last 12 months. I do feel it's close, though, particularly with Eltoprazine. Hope to learn of that sooner rather than later.